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Dr Amindoi:10.1016/j.jtcvs.2005.10.034Objective: Robotic systems allow surgeons to perform minimally invasive cardiac
surgery in adults. Experience in the pediatric population, however, is limited.
Perventricular closure of muscular ventricular septal defects has been reported in
humans but requires a median sternotomy. The objective of this study was to assess
the feasibility of robotically assisted closure of perimembranous ventricular septal
defects by using the perventricular approach.
Methods: The procedure was attempted in 7 pigs with naturally occurring perimem-
branous ventricular septal defects. Echocardiography was performed to confirm the
presence and assess the size of the defect. A 3-armed da Vinci system consisting of
two 8-mm instrument ports and a 12-mm endoscopy port was used. A pericardio-
tomy was performed, and the right ventricular free wall was visualized. A spinal
needle was advanced into the right ventricular cavity. By using echocardiographic
guidance, a glide wire was advanced through the angiocatheter and manipulated
through the defect into the left ventricle or the ascending aorta. A delivery sheath
was advanced over the wire. An appropriately sized Amplatzer device was deployed
through the sheath.
Results: The procedure was successful in 5 pigs. One device was removed because
it was smaller than the defect and an appropriately sized device was not available.
The placement failed in the second pig in the series. Four pigs were followed up for
1 to 4 months. Angiograms performed before the pigs were killed documented
complete occlusion in 3 and mild-to-moderate shunt in 1.
Conclusions: Robotically assisted perventricular closure with the Amplatzer Mem-
branous VSD Occluder is feasible. This approach avoids the associated morbidities
of cardiopulmonary bypass and median sternotomy. Further investigation and
refinements are needed, however, before application of this approach in humans.
Perimembranous ventricular septal defect (VSD) is one of the most commoncongenital cardiac defects.1 Since the first successful surgical closure of VSDby Lillehei,2 open repair by using cardiopulmonary bypass (CPB) has been
considered the gold standard. As survival after surgery for congenital heart defects
has improved, the focus has shifted toward minimizing morbidity by using a variety
of methods, among them minimally invasive surgical techniques and strategies that
minimize or eliminate the use of CPB.3 The robotic Da Vinci Surgical System
(Intuitive Surgical, Sunnyvale, Calif) has been successfully used for a variety of
procedures in the adult population, including intracardiac repairs, but its application
in the pediatric population has been limited.4,5 Furthermore, many minimally
invasive or port access methods require CPB support via femoral cannulation. CPB
through the femoral vessels in the pediatric population may not be feasible because
the femoral vessels may be too small. Perventricular device closure of muscular
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DVSD has been demonstrated to be a highly successful and
low-risk procedure.6-9 This technique avoids the morbidity
inherent to CPB10 but requires median sternotomy. It also
avoids the peripheral vascular complications associated
with catheter-based device delivery and expands the avail-
ability of device closure to patients who would otherwise
not be candidates for catheter-based therapy because of size
restrictions or anatomic factors.
The recently developed Amplatzer Membranous VSD Oc-
cluder (AGA Medical Corporation, Golden Valley, Minn)
has been successfully used to close perimembranous VSD
in children by using the transcatheter technique. Perven-
tricular deployment of the membranous device via median
sternotomy has been reported in animals. With the adjunc-
tive use of a robotic system, median sternotomy can be
avoided in addition to avoiding CPB. Avoiding sternotomy
and CPB should decrease the overall morbidity. The objec-
tive of this study was to evaluate the safety and feasibility of
VSD closure with the da Vinci system and the perventricu-
lar technique.
Materials and Methods
All animals received humane care in compliance with the “Guide
for the Care and Use of Laboratory Animals” prepared by the
Institutes of Laboratory Animal Resources and published by the
National Institutes of Health (publication no. 86-223, revised
1985). The study was approved by the Institutional Animal Care
and Use Committee of the University of Nebraska Medical Center
(Omaha, Neb).
Animal Model
Yucatan pigs, which have a naturally occurring perimembranous
VSD, were used in the study. The perimembranous defect in these
pigs is anatomically similar to that found in humans. The defect is
located just beneath the anteroseptal commissure of the tricuspid
valve. On the left ventricular side, the defect is subaortic. The rate
of aneurysm formation seems to be higher in pigs than in humans,
and, hence, spontaneous closure may also be higher. The course of
the conduction system in relation to the defect remains unknown.
Atrioventricular block after device closure has not been reported in
the Yucatan model.
The Device
The Amplatzer Membranous VSD Occluder is made from 0.005-
inch nitinol wires. The device has been described in detail previ-
ously.11 In brief, the device is self-expanding and self-centering
and can be delivered through a 7F through 9F delivery sheath.
Sheath size depends on the size of the device chosen for closure.
Abbreviations and Acronyms
CPB  cardiopulmonary bypass
VSD ventricular septal defectThe wires are woven to form 2 connecting disks that are connected
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The waist of the device corresponds to the size of the defect. The
left disk is eccentric in design; the portion of the device that is to
face the aortic valve is flat instead of round. The flat-edge design
is meant to avoid impingement of the aortic cusps. The delivery
sheath has a coaxial system and is designed to lock the device so
that at the time of deployment, the flat edge of the device will face
the aortic valve. The edge of the device that is to face the left
ventricle apex is 5.5 mm larger than the waist. The right-sided disk
is 2 mm larger than the waist in its entire circumference. A
platinum marker is present on the left disk; this marker helps the
operator maintain an optimal device orientation at the time of the
delivery. The marker is placed on the side of the disk that is to
face the left ventricular apex. On fluoroscopy, the marker should
be at 1800 hours in the left anterior oblique view with cranial tilt.
Echocardiogram
Transesophageal echocardiographic images are not obtainable in
Yucatan pigs; therefore, intraoperative transthoracic echocardiog-
raphy was performed. With the animal in the left decubitus posi-
tion, transthoracic echocardiography was performed by using a
commercially available 2-dimensional echocardiographic imaging
system with color flow mapping and pulsed and continuous-wave
Doppler capabilities. Imaging frequencies ranged from 3 to 8
MHz. Most examinations required the lower frequencies for opti-
mal ultrasound penetration. Modified apical and long-axis 2-
dimensional echocardiographic views were most commonly ob-
tained from the anterior left axillary line transducer position. Wide
variations in cardiac position and orientation within the thorax
were encountered from animal to animal, so a search for the point
Figure 1. Layout of the operating room suite with the positions of
the anesthesia, echocardiographer, anesthetist, and surgeon shown.on the chest wall that yielded optimal imaging was required in
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Deach case. Color flow mapping aided in the rapid identification of
the VSD. Once the defect was located, its proximity to the aortic
and tricuspid valves was evaluated. A search for preintervention
pathologic flow disturbances across the cardiac valves was under-
taken by using color flow mapping. Digital measurements of the
VSD diameter were obtained from freeze-frame images of the
2-dimensional image and from the breadth of the color Doppler
shunt signal on the flow map. Positioning of the device delivery
apparatus, the delivery of the device, and its release were moni-
tored echocardiographically. The final position of the device rel-
ative to the defect and neighboring cardiac valves was evaluated
on the 2-dimensional images in multiple planes, and any new or
persistent pathologic flow disturbances upon device delivery and
release were noted.
The Procedure
The general outline of the operating room suite is depicted in
Figure 1. All procedures were performed under single-lumen gen-
eral endotracheal tube anesthesia with standard anesthesia moni-
toring. A certified veterinary anesthetist was present and delivered
the anesthesia at all times. The animals were positioned in a
modified (10°) left lateral decubitus position on the operating
table. The forelimbs were retracted cephalad and to the left by
using soft restraints. A soft roll was placed under the scapula to
widen the intercostal spaces. A 3-armed da Vinci Surgical System
was then positioned at the left side of the table, with the surgeon
at the right side of the table. The head of the table and the vision
cart were positioned at the foot of the table. The robotic surgeon
was positioned at the master surgeon’s console away from the
operative field (Figure 1). The components and operation of the da
Vinci Surgical System have been described previously.5 In brief, 3
Figure 2. Robotically assisted pericardiotomy. RV, Right ventri-
cle; RA, right atrium; Ao, aorta; LV, left ventricle; PA, pulmonary
artery; LAA, left atrial appendage.ports were used for all operations: an 8-mm left da Vinci instru-
The Journal of Thoraciment port 3 to 4 cm lateral to the right sternal border in the most
cephalad intercostal space possible, a 12-mm endoscopic port
placed 6 to 8 cm caudal and 1 to 2 cm lateral to the left instrument
port, and one 8-mm right da Vinci instrument port placed 6 to 8 cm
caudal to the endoscopic port and 3 to 4 cm lateral to the right
sternal border. A 12-mm, 30° stereo endoscope in the angled-down
position provided the best visualization. A thoracotomy was not
performed. Carbon dioxide insufflation was not necessary.
A pericardiotomy was performed anterior to the phrenic nerve
by using robotic hook electrocautery and forceps and was extended
sufficiently to allow wide visualization of the right ventricular free
wall and the outflow tract (Figure 2).2 The delivery sheath was
inserted percutaneously into the right ventricular free wall. Once
the delivery sheath was successfully positioned (see below), a
double armed 4-0 monofilament purse-string suture was roboti-
cally placed around it and held under tension to ensure hemostasis
at the right ventricular puncture site during device deployment.
After successful closure and removal of the sheath, the purse string
was tied securely with the help of robotic instruments.
The technique of perventricular closure of VSD with the Am-
platzer Membranous VSD Occluder in Yucatan pigs has been
described previously.11 All procedures were performed with the
help of transthoracic echocardiography guidance. The VSD was
measured in 2 views. A 16-gauge spinal needle (Cook Inc, Bloom-
ington, Ind) was advanced through the fifth intercostal space
(Figure 3) and clearly visualized endoscopically (Figure 3, a). The
right ventricular free wall was punctured at the desired location,
and the needle was visualized in the right ventricular cavity by
echocardiography (Figure 3, b). The stylet was removed, and a
glide wire (Meditech, Boston Scientific Corporation, Natick,
Mass) was advanced through the needle into the right ventricular
cavity (Figure 4) and then manipulated across the VSD into the left
ventricle or the ascending aorta (Figure 4, A). The spinal needle
was removed, and a 9F dilator was advanced over the wire to
predilate the entry before advancing the delivery sheath. A deliv-
ery sheath was advanced over the wire into the left ventricular
Figure 3. A, The spinal needle introduced through the chest wall.
B, The stylet is removed. Ao, Aorta; VSD, ventral septal defect; RV,
right ventricle; PA, pulmonary artery.cavity (Figure 4, B), and its position was confirmed by echocar-
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Ddiography. The dilator and the wire were removed, and the sheath
was allowed to back-bleed to remove any entrapped air. The sheath
was gently flushed with saline. An appropriately sized Amplatzer
Membranous VSD Occluder was immersed in saline and screwed
onto the delivery cable. The device was loaded with the help of a
loader and advanced through the delivery sheath. Once the device,
which was visible while within the sheath, was seen to cross the
VSD by echocardiography, the sheath was withdrawn, and the left
disk was deployed. If the orientation of the left disk seemed
suboptimal, then the sheath was rotated until optimal orientation
was achieved. The device and the sheath were pulled back together
to approximate the left disk to the ventricular septum. The right
disk was then deployed (Figure 4, C). The position of the device
was again confirmed, and the integrity of the aortic and the
tricuspid valves was evaluated. The device was released by anti-
clockwise rotation of the delivery cable (Figure 4, C). After
removal of the sheath and tying of the purse-string suture, hemo-
stasis was verified, all ports were removed, and all port sites were
closed with absorbable sutures. All animals were extubated in the
operating room and recovered under monitored care for several
hours. Once stable, the animals were returned to the animal facility
for the remainder of their postoperative course.
During follow-up, the animals were monitored for signs of
wound infection, pneumonia, and other postoperative complica-
tions. At the conclusion of the follow-up, cardiac catheterization
Figure 4. A, Glide wire inserted through the needle and VSD and
into the aorta. B, The delivery sheath introduced over the wire. C,
The device introduced through the delivery sheath, attached to
the delivery cable. D, The device has been released. Ao, Aorta;
VSD, ventral septal defect; RV, right ventricle; PA, pulmonary
artery; LV, left ventricle; LAA, left atrial appendage.with left ventricular and ascending aortic angiography was per-
430 The Journal of Thoracic and Cardiovascular Surgery ● Febrformed to evaluate VSD closure and aortic valve function. The
animals were then killed for autopsy evaluation.
Results
VSD closure was attempted in 7 pigs (age, 245-384 days;
weight, 35-74 kg). The mean follow-up for all pigs with
successful closure was 31 days (range, 1-100 days).
The procedure was successful in 6 pigs, and device place-
ment was successful in 5. The first pig was killed at the
conclusion of the procedure to directly examine the deployed
device and its position. The remaining 4 pigs were observed
for a minimum of 1 month before they were killed. Left
ventricular angiography revealed complete closure of the VSD
in 3 and mild to moderate shunt in 1. This pig had aneurysm
formation with multiple holes on the right ventricular side.
Aortic angiography revealed no evidence of aortic insuffi-
ciency in any pig. No evidence of heart block or arrhythmia
was seen with continuous electrocardiographic monitoring
during cardiac catheterization.
In 2 pigs, the procedure was unsuccessful. The wire was
not able to be passed through the defect in 1 pig, and in the
other pig, the device was not released because an appropri-
ately sized device was not available.
Examination of the heart of the pig that was killed on the
day of the procedure revealed proper device orientation and
position without encroachment of the aortic or the tricuspid
valve. Autopsy of the other pigs also showed acceptable
position and orientation of the device in each case.
Discussion
Perventricular device closure of VSD offers many advan-
tages over other forms of therapy, including avoidance of
CPB and applicability for patients who are too small for
catheter-based therapy. Until now, the perventricular method
has been used with a median sternotomy. Robotic systems
have been used to avoid minimally invasive cardiac surgery,
thus avoiding the morbidity of a full sternotomy. Because of
the freedom of movement of their tips, they have a signif-
icant technical advantage over traditional endoscopic instru-
mentation. However, endoscopic instruments are cheaper
and could potentially be used for the same purpose.
This is the first report of successful perventricular VSD
closure by using robotic assistance. The blending of these 2
technical elements creates the ability to correct a common
intracardiac defect without CPB or median sternotomy. This
latter point is particularly important for the VSD patient,
who most often requires therapy early in infancy. It is
important to note that to be able to close defects in the
younger population, we will need smaller ports, which may
become available in the future. Further miniaturization of
ports and instruments will facilitate the application of this
technology even in neonates.
Since its introduction in 1997, perventricular device clo-
sure has been successfully applied in more than 40 patients
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Dwith muscular VSD and 3 patients with perimembranous
VSD (unpublished data). For muscular VSD, the procedure
requires a complete sternotomy or ministernotomy. The
defects are closed under transesophageal echocardiographic
guidance. The delivery of the device and its placement are
relatively easy because echocardiographic images are ex-
cellent. In pigs, the echocardiography pictures were not
optimal because of several limitations. First, transesopha-
geal echocardiography cannot be performed. Second, trans-
thoracic pictures are suboptimal in pigs because the heart is
midline in position. Third, the significant thickness of the
chest wall limits ultrasound penetration. Fourth, the physi-
cal space available to perform echocardiography was very
limited because of the robotic ports and the left decubitus
position of the pig at the time of the procedure. We believe
that these issues will be resolved when the procedure is
attempted in humans, especially because transesophageal
echocardiography will be performed with optimal echocar-
diographic images.
Introduction of the needle into the right ventricle will be
easier in humans because of the standard familiarity of the
heart position and orientation in human beings. Despite all
the challenges, with refinements, we believe that the VSDs
will be closed successfully in humans with robotic assis-
tance. When the instrument ports and endoscopes become
smaller, the technique can be used in humans. With the
currently available size of the ports, it is not possible to use
this technique in small children.
It is predicted that in the near future, robotic assistance
will be an attractive option for patients and families because
it will help in improving the cosmetic appearance of the
patients, will decrease morbidity and hospital stay, and will
be a favorable alternative to percutaneous closure in small
children. The advantages of perventricular closure include
the following: no CPB or its associated complications, no
fluoroscopy-related or cardiac catheterization–related com-
plications, and the ability to close defects that are otherwise
difficult to close when the patient is on CPB.
In summary, this study demonstrates that robotically
assisted perventricular closure of VSDs is feasible. It has the
potential of minimizing morbidity associated with VSD clo-
sure, improving cosmesis, and expanding the patient popu-
lation to whom device closure of defects may be offered.
The authors are grateful to Dr Emile Bacha for his valuable
suggestions in reviewing the manuscript.
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Discussion
Dr Richard G. Ohye (Ann Arbor, Mich). Before I start, I should
preface some of my comments with saying I do believe that this is
important technology, but I will take a little bit of the devil’s
advocate role here. I have 2 somewhat related questions.
Dr Amin, in your background slides and also in your conclu-
sions, you cite open sternotomy with CPB as one of the compar-
isons, as well as cardiac catheterization–based closure, and you
cite that some of the disadvantages are the need for CPB as well as
the full sternotomy, which I think is probably not the proper
comparison. I have done these, and they can be done through a
little mini subxiphoid incision without CPB.
In the comparison with cardiac catheterization–based interven-
tion, you note that it is difficult to do this in less than 8 kg in the
catheterization laboratory, and certainly most literature would say
that less than 15 kg is the limit for da Vinci approaches. I have
done them as low as 10 kg, but it does become challenging at that
size. You also note that concomitant lesions may be a problem in
the catheterization laboratory, but again, that is the same for da
Vinci closure; you can’t do concomitant lesions either. So I think
the more appropriate comparison would be an off-bypass with a
small subxiphoid approach. I would like to know what you think
the advantages are of using the robotic approach for that.
A related question, in a more global sense: How do you
convince the chief financial officer of your hospital to buy this $1
million plus instrument with over a $100,000 a year cost for
disposables and maintenance to do operations that are actually
going to cost the hospital money? As you are well aware, the most
lucrative patient for a hospital is the patient who has an operation,
goes to the intensive care unit for a day or two, goes to the floor
for another 2 or 3 days, and then goes home. So you are going to
ask him to buy a very expensive piece of equipment to actually
cost them money in patient care as well. Although I think this is
c and Cardiovascular Surgery ● Volume 131, Number 2 431
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Dimportant technology, the 2 questions I have are as follows: First,
what are the advantages of a da Vinci closure versus a small
subxiphoid approach? Second, in a more global sense, what do you
think the importance and the advantages of robotic approaches
are?
I would like to congratulate Dr Amin on a very interesting
paper and an attempt to advance technology that I think will be
very important in the future.
Dr Amin. I think there is definite advantage in using a robotic
system with the perventricular approach. I agree with you that the
weight limit for da Vinci system is 15 kg and hence does not
appear feasible at the current time. In the future, however, as we
progress further, this technique will only get better. I believe that
the subxiphoid approach is a feasible technique for certain proce-
dures, but with robotic assistance, our access to the heart will
improve, and the chance of repairing defects will improve in the
future, as this technology improves.
Second, I agree with you, it is costly, but then everything is
costly nowadays. We use the robots all the time in the research
laboratory to improve our patient care, and I think, given that
reason, and the more we refine, it will ultimately pay for its cost.
We cannot be satisfied with our improved results so much that we
stop exploring techniques that may advance medical science.
Dr Ludwig K. von Segesser (Lausanne, Switzerland). We have
used Amplatzer devices for sealing off transventricular access
orifices in valve stent implantations, and I wanted to ask you what
blood loss you observed for robotic closure in your application.
Dr Amin. During this experiment in the first 3 pigs, when
our procedure time was longer and we actually had to puncture
the right ventricular free wall more than once to find the appro-
priate spot through which we could advance the wire, I would say
the blood loss was at least 30 to 50 mL. In the last 4 pigs where we
performed this procedure, the blood loss was less than 10 mL.
Dr Pedro del Nido (Boston, Mass). Dr Amin, I would like to
echo some of your comments. If we use cost as a way to limit our
exploration of new technology, we are going to do very little that
is new. The question I have relates to imaging. You used trans-
esophageal echo, which in the pig is very challenging. Did you do432 The Journal of Thoracic and Cardiovascular Surgery ● Febran ideal world, what would you use for your imaging technology
if you could use multimodality imaging?
Dr Amin. Thank you, Dr del Nido. We used transthoracic echo
for this protocol because, as you said, transesophageal echocardi-
ography cannot be performed in pigs. The perventricular closure in
humans is performed under transesophageal or epicardial echocar-
diographic guidance. Ideally, I would be very tempted to use
3-dimensional echocardiography, if that was available, and we are
planning to use it in the future experiments.
Dr Emile Bacha (Chicago, Ill). Congratulations, Dr Amin. I
think you should continue to pursue this line of work. My question
relates to what your goal is. As Dr Ohye was saying, the subxi-
phoid approach does afford very good exposure to the heart, but
you are not limited to the subxiphoid approach. You can also do a
small thoracic incision that would give you access to different
planes to the ventricle, and I do think that the goal here is a
transthoracic puncture through the chest wall into the ventricle and
then delivery of the device. In that sense, the robot would be just
a step on the way and eventually would probably be discarded in
that technique.
Do you see any devices coming up whereby you could control
the ventricular puncture from a remote approach, such as a trans-
thoracic approach, without placing a suture on the ventricle?
Dr Amin. I am very much familiar and know that you have
done a significant number of cases with a perventricular approach.
Most of the time when we puncture the right ventricular free wall,
the bleeding is through the angiocatheter. Once that is stopped
there is usually no bleeding. At the current time, I am not aware of
any device or technique that will allow us to perform this proce-
dure without placing a suture on the right ventricular free wall. I do
believe it will be doable in the future.
Regarding the advantage of robots, as I was trying to explain to
Dr Ohye, I think it will have an advantage, because I think the
perimembranous VSDs are more difficult to cross, and even if you
want to do the procedure through a subxiphoid approach, it may be
more difficult. Having said that, yes, you are right, you can do a
small thoracotomy on the right side and use that approach, but I
believe that we should keep experimenting and see what will beanything special to actually be able to view the structures well? In the best way to do so in the future.uary 2006
